Santoni L - Search Results

1

The cost of first-ever stroke in Valle d'Aosta, Italy: linking clinical registries and administrative data.

Bottacchi E, Corso G, Tosi P, Morosini MV, De Filippis G, Santoni L, Furneri G, Negrini C. Bottacchi E, et al. Among authors: santoni l. BMC Health Serv Res. 2012 Oct 30;12:372. doi: 10.1186/1472-6963-12-372. BMC Health Serv Res. 2012. PMID: 23110322 Free PMC article.

2

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.

Furneri G, Santoni L, Ricella C, Prosperini L. Furneri G, et al. Among authors: santoni l. BMC Health Serv Res. 2019 Jun 28;19(1):436. doi: 10.1186/s12913-019-4264-1. BMC Health Serv Res. 2019. PMID: 31253138 Free PMC article.

3

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.

Paolicelli D, Iannazzo S, Santoni L, Iaffaldano A, Di Lecce V, Manni A, Lavolpe V, Tortorella C, D'Onghia M, Direnzo V, Puma E, Trojano M. Paolicelli D, et al. Among authors: santoni l. PLoS One. 2016 Jul 8;11(7):e0159214. doi: 10.1371/journal.pone.0159214. eCollection 2016. PLoS One. 2016. PMID: 27390865 Free PMC article.

4

Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.

Moccia M, Loperto I, Santoni L, Masera S, Affinito G, Carotenuto A, Lanzillo R, Triassi M, Morra VB, Palladino R. Moccia M, et al. Among authors: santoni l. Neurodegener Dis Manag. 2022 Jun;12(3):109-116. doi: 10.2217/nmt-2021-0038. Epub 2022 Apr 21. Neurodegener Dis Manag. 2022. PMID: 35446149 Free article.

5

An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.

Wilson K, Hettle R, Marbaix S, Diaz Cerezo S, Ines M, Santoni L, Annemans L, Prignot J, Lopez de Sa E. Wilson K, et al. Among authors: santoni l. Eur J Prev Cardiol. 2012 Oct;19(5):1173-83. doi: 10.1177/1741826711420345. Epub 2011 Aug 12. Eur J Prev Cardiol. 2012. PMID: 21840967 Clinical Trial.

6

Author Correction: Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.

Moccia M, Santoni L, Vaccari I, Affinito G, Caliendo D, Rubba F, Lanzillo R, Triassi M, Brescia Morra V, Palladino R. Moccia M, et al. Among authors: santoni l. Eur Rev Med Pharmacol Sci. 2024 Feb;28(4):1241. doi: 10.26355/eurrev_202402_35445. Eur Rev Med Pharmacol Sci. 2024. PMID: 38436157 Free article.

7

Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.

Moccia M, Santoni L, Vaccari I, Affinito G, Caliendo D, Rubba F, Lanzillo R, Triassi M, Brescia Morra V, Palladino R. Moccia M, et al. Among authors: santoni l. Eur Rev Med Pharmacol Sci. 2024 Jan;28(1):411-418. doi: 10.26355/eurrev_202401_34930. Eur Rev Med Pharmacol Sci. 2024. PMID: 38235893 Free article.

8

Distinct effects of type 2 diabetes and obesity on cardiopulmonary performance.

Nesti L, Pugliese NR, Santoni L, Armenia S, Chiriacò M, Sacchetta L, De Biase N, Del Punta L, Masi S, Tricò D, Natali A. Nesti L, et al. Among authors: santoni l. Diabetes Obes Metab. 2024 Jan;26(1):351-361. doi: 10.1111/dom.15324. Epub 2023 Oct 12. Diabetes Obes Metab. 2024. PMID: 37828824

9

Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.

Filippi M, Grimaldi L, Conte A, Totaro R, Valente MR, Malucchi S, Granella F, Cordioli C, Brescia Morra V, Zanetta C, Perini D, Santoni L; EASIER Study Working Group. Filippi M, et al. Among authors: santoni l. J Neurol. 2024 Jan;271(1):340-354. doi: 10.1007/s00415-023-11955-0. Epub 2023 Sep 16. J Neurol. 2024. PMID: 37715789 Free PMC article.

10

Tris(β-ketoiminate) Aluminium(III) Compounds as Aluminium Oxide Precursors.

Douglas SP, Faria EN, Mrig S, Zhou Y, Santoni L, Clancy AJ, Knapp CE. Douglas SP, et al. Among authors: santoni l. Chempluschem. 2023 Jan;88(1):e202200411. doi: 10.1002/cplu.202200411. Chempluschem. 2023. PMID: 36646521

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page